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Abstract
Background: QuantiFERON-TB Gold In-Tube (QFT-GIT) is considered an alternative to the tuberculin skin test (TST) for the
diagnosis of tuberculosis (TB) infection, but the programmatic impact of QFT-GIT implementation is largely unknown. In
March, 2010, the Baltimore City Health Department (BCHD) introduced routine QFT-GIT testing for individuals referred to
the TB program for suspected latent TB infection (LTBI).
Design: Retrospective study comparing LTBI diagnosis and treatment during the 13 months before and after QFT-GIT
implementation at the BCHD TB clinic.
Results: 607 and 750 individuals were referred by community-providers for suspected LTBI in the pre- and post-QFT-GIT
periods, respectively. Most individuals in the pre- and post-QFT-GIT periods were referred on the basis of a positive TST
(597/607 [98%] vs. 690/750 [92%], respectively) and were foreign-born (363/607[59%] vs. 507/750[68%], respectively). BCHD
performed QFT-GIT testing for 375/543 (69%) eligible individuals in the post-QFT-GIT period, of which 185 (49%) were
positive, 178 (47%) were negative, 1 (0.25%) was indeterminate, and 11 (3%) did not yield results. Concordance of QFT-GIT
with TST was low (183/352[52%]). Foreign-born individuals had higher proportions of QFT-GIT positivity (57%) than US-born
individuals (36%; AOR 3.3 [95%CI 1.7–6.2]). Significantly fewer individuals received a final diagnosis of LTBI in the post-QFT-
GIT period (397/567 [70%]) compared to the pre-QFT-GIT period (445/452 [98%], p,0.001). In the post-QFT-GIT period, only
230/399 (58%) of those receiving QFT-GIT testing had a final diagnosis of LTBI, while 167/168 (99%) of those without QFT-
GIT testing were diagnosed with LTBI (p,0.001). There was no difference in treatment initiation between those with and
without QFT-GIT testing (175/230 [76%]) vs. 133/167 [80%], respectively) in the post-QFT-GIT period.
Conclusion: QFT-GIT implementation for LTBI evaluation in a public health clinic significantly reduced the proportion of
referred individuals in whom LTBI was diagnosed. QFT-GIT testing had no impact on treatment initiation or completion
among those diagnosed with LTBI.
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Introduction
Testing and treatment of persons at increased risk for latent
tuberculosis infection (LTBI) is a core element of the tuberculosis
(TB) elimination strategy in the United States (US) [1,2,3]. The
tuberculin skin test (TST) is widely utilized for detection of M.
tuberculosis infection, but this test has important limitations. The
TST can cross-react with non-tuberculous mycobacterial (NTM)
species or Bacille Calmette Guerin (BCG) vaccine, thereby
complicating the interpretation of TST results especially in
BCG-vaccinated foreign-born individuals from TB-endemic set-
tings. Additionally, TST results are subject to inter-reader
variability and may differ by level of training of those reading
the test [4]. These limitations may reduce TST specificity, and
may reduce patient and provider confidence in TST results.
Interferon-gamma (IFN-c) release assays (IGRAs), such as the
commercially available QuantiFERON-TB Gold In Tube (QFT-
GIT, Cellestis, Ltd, Carnegie, Australia) test, have the potential to
overcome some of TST’s limitations. QFT-GIT detects M.
tuberculosis (MTB) infection by measuring in vitro IFN-c release
following stimulation of lymphocytes with antigens specific to M.
tuberculosis, ands has several potential advantages over TST. QFT-
GIT retains specificity in BCG-vaccinated populations and has less
cross-reactivity than TST with NTM species [5,6,7]. QFT-GIT
has similar or potentially increased sensitivity compared with TST
based on a recent meta-analyses of the literature [6]. Since QFT-
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those of TST. Recently the U.S. Centers for Disease Control and
Prevention (CDC) provided guidance that IGRAs are an accept-
able alternative to TST for the detection of M. tuberculosis infection,
and are the preferred option in some circumstances including
testing of BCG-vaccinated populations [7].
While many research studies have been conducted to assess
IGRA test performance, there is limited information about the
implementation of these tests in the context of public health TB
control programs [8,9,10]. Results from a limited San Francisco
Department of Public Health program to substitute TST with
QFT-GIT suggested that QFT-GIT testing was feasible with
results more readily available than TST results [8]. In Alberta,
Canada QFT-GIT was used as a confirmatory test for patients
with a positive TST who were referred to a TB clinic. They found
only 40% of patients referred for a positive TST were QFT-GIT
positive, suggesting possible high proportions of false-positive TST
results due to BCG vaccination or misreading of TSTs [9].
Whether QFT-GIT can be successfully implemented into other
local health department TB programs, and the ultimate pro-
grammatic impact on LTBI diagnosis and treatment remains
unclear.
The Baltimore City Health Department (BCHD) TB control
program clinic (‘‘BCHD TB clinic’’) provides TB clinical care
services free-of-charge to residents of Baltimore City, population
620,961, with active TB incidence of 5.2/100,000 in 2010[11].
With respect to M. tuberculosis infection, a main BCHD TB clinic
activity is the evaluation and clinical management of individuals
with suspected M. tuberculosis infection referred from community
providers. Within Baltimore City, a variety of clinical care
providers perform M. tuberculosis infection testing, almost exclu-
sively using TST, for a number of indications including
employment testing, immigration/refugee services, homeless
services, and as a requirement for attendance in some drug-
treatment programs. Individuals identified with possible M.
tuberculosis infection (typically individuals with a positive TST) by
community sources are referred to the BCHD TB clinic for further
evaluation and treatment. Prior to March 2010, the BCHD TB
clinic made decisions on LTBI diagnosis and treatment based
upon test results (i.e. TST in most cases) available from the referral
source. In March 2010, the BCHD TB clinic decided to
implement a new testing program in which QFT-GIT was made
available as part of normative clinical care during evaluations for
individuals referred with suspected M. tuberculosis infection. We
sought to formally evaluate the programmatic impact of QFT-
GIT implementation in the BCHD TB program. We assessed the
uptake of QFT-GIT testing and availability of interpretable
results, and compared programmatic rates of LTBI diagnosis and
treatment before and after QFT-GIT implementation. Additional
analyses attempted to determine factors associated with QFT-GIT
test positivity and concordance with TST.
Methods
Ethics Statement
This retrospective study was approved by ethics committees at
the Johns Hopkins University School of Medicine (Baltimore,
USA) and the Baltimore City Health Department. This study
received a waiver of informed consent; this research involved no
more than minimal risk to subjects, data was collected solely by
review of existing laboratory and medical records, and this
research could not practicably be carried out without the waiver of
informed consent.
QFT-GIT Implementation
The BCHD TB clinic initiated QFT-GIT testing on March 1,
2010 as part of their normative care algorithms. Following March
2010, staff routinely obtain blood for QFT-GIT testing on all
individuals referred for suspected M. tuberculosis infection who had
not had prior QFT-GIT testing from the referral source. Clinical
care staff underwent manufacturer-supervised training in filling
the tubes during phlebotomy, and in how to label and send tubes
to the single off-site laboratory located approximately 3 miles away
prior to QFT-GIT implementation into routine practice. The four
prescribing clinicians (2 MDs and 2 Nurse Practitioners) were
trained in interpretation of QFT-GIT test results and CDC
recommendations [7]. Manufacturer representatives trained lab-
oratory personnel in the correct performance of the assay. Within
the BCHD TB clinic no incubator was available, and tubes are
transported once per day at approximately 2 pm from the clinic to
the testing laboratory. Within BCHD TB clinic, clinicians are
allowed to use clinical judgment and not send QFT-GIT test if
blood cannot be readily obtained from an individual, or if the
specimen transport courier has already completed specimen pick-
up for the day.
Study Design
We conducted a retrospective cohort study to evaluate LTBI
services before and after implementation of the QFT-GIT test in
the BCHD TB program, and assessed concordance of QFT-GIT
with TST during routine clinic conditions. Data was obtained
using the BCHD TB Program electronic database (Microsoft
Access 2003) and through chart reviews. We compared 13 months
of data prior to QFT-GIT introduction (pre-QFT-GIT) with the
13 month period after QFT-GIT implementation (post-QFT-
GIT). Patients were assigned to the pre-QFT-GIT period if they
were referred or evaluated between Feb 1, 2009 and Feb 28, 2010;
patients were assigned to the post-QFT-GIT period if they were
referred or evaluated between March 1, 2010 and March 31,
2011.
Study Population
Individuals referred to the BCHD TB clinic for suspected M.
tuberculosis infection were included without age restriction. Indi-
viduals are referred to BCHD for evaluation on the basis of
a positive TST, positive IGRA test, or an immigration B-Waiver
(individuals with evidence of inactive TB infection on chest
radiographs at the time of immigration). Individuals with active
TB and their close contacts were excluded.
LTBI evaluation at BCHD
Per routine care, all individuals referred for M. tuberculosis
infection evaluation were interviewed by a BCHD TB clinic staff
member for demographic information, medical history, and signs
and symptoms of active TB; a chest x-ray and liver chemistries
were obtained, and HIV testing was offered. TST and QFT-GIT
were not repeated for individuals who had one or both tests
performed by a community provider. Patients with signs or
symptoms of active TB were evaluated further by sputum smear
microscopy, culture, and other testing as indicated.
Latent TB diagnosis and treatment
Prior to March 1, 2010, diagnosis of LTBI was based on
available TST or IGRA information from the referral source at
the time of referral to the BCHD TB clinic. Starting March 1,
2010, BCHD directed QFT-GIT testing was made available as
part of the diagnostic evaluation. Individuals with discordant
QFT-GIT Implementation in Baltimore City
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the discretion of the BCHD TB clinician. Factors considered by
clinicians included but were not limited to HIV status, chest x-ray
results, age of individual, degree of TST induration, and QGIT
antigen and nil results, country of origin, BCG status, and other
TB risk factors. Individuals diagnosed with LTBI during both
study periods were offered treatment in accordance with published
guidelines, with medications dispensed on a monthly basis after
monthly follow-up BCHD TB clinic visits including toxicity
assessment [12,13].
QFT-GIT testing
QFT-GIT testing was performed according to manufacturer’s
instructions at a single off-site BCHD laboratory [14]. Phlebotomy
for QFT-GIT testing occurred at the BCHD TB clinic at the time
of the patient’s initial clinical evaluation. Samples were stored at
room temperature for up to 6 hours at the BCHD TB clinic until
transportation to the laboratory via a daily courier service.
Following incubation and centrifugation, harvested plasmas were
stored at 4uC for up to 17 days prior to ELISA testing. Results
were calculated and interpreted by the assay software as positive,
negative, or indeterminate, according to manufacturer’s instruc-
tions– tests were interpreted as indeterminate if the Mitogen minus
Nil was ,0.5, or the Nil was .8.0; tests were interpreted as
negative if the TB antigen minus Nil was ,0.35, or if the TB
antigen minus nil was $0.35 but was ,25% of the Nil value; tests
were interpreted as positive if the TB Antigen minus Nil was
$0.35 and was $25% of the Nil value [14].
Statistical Considerations
The primary objectives of this study were to determine the
proportions of LTBI diagnosis and subsequent treatment initiation
among individuals referred to BCHD for TB evaluation,compar-
ing the pre-QFT-GIT and post-QFT-GIT period. Additional
analysis sought to determine proportions of QFT-GIT positivity
among those referred to BCHD for LTBI care, to assess the
percent agreement between TST and QFT-GIT, and to assess
factors associated with QFT-GIT positivity and concordance with
TST. Categorical data were compared using x
2 tests. Factors
associated with QFT-GIT results and TST concordance were
assessed using univariate and multivariate logistic regression
analysis. Analysis of treatment completion was restricted to those
who started a 9 month INH regimen prior to Nov 30, 2010 or
a 4 month Rifampin regimen prior to March 30, 2011, to allow
time for treatment completion. Data were analyzed using STATA
(version 10.1, StataCorp, College Station, Texas).
Results
Study Population
Table 1 shows demographic features of individuals referred to
the BCHD TB clinic for suspected M. tuberculosis infection. There
were more referrals in the post-QFT-GIT period (750) compared
to the pre-QFT-GIT period (607, p,0.01). Among referrals, there
was no difference in age, sex, or HIV status comparing the two
study periods (Table 1). However, compared to the pre-QFT-GIT
period, the post-QFT-GIT period had a greater proportion of
individuals identified as being foreign-born (68% post-QFT-GIT
compared to 59% pre-QFT-GIT, p=0.003). The most common
countries of origin among foreign-born in the pre-QFT-GIT
period were from Nepal (58/363 [16%]), Bhutan (54/363 [15%]),
Burma (22/363[6%]), and Iraq (21/363[6%]). In the post-QFT-
GIT period the most common countries of origin for foreign-born
were from Nepal (72/507[14%]), Bhutan (62/507[12%]), Mexico
(40/507 [8%]), Iraq (25/507[5%]), Ethiopia (25/507[5%]) and
Eritrea (25/507[5%]). The referring sources also differed slightly
between the two study periods–there was a decline in the
percentage of referrals from drug treatment programs and an
increase in the percentage of referrals from health fairs (targeting
the Latino community) and B-waivers in the post-QFT-GIT
period compared to the pre-QFT-GIT period (Table 1). In the
pre-QFT-GIT period, 597/607(98%) were referred on the basis of
a positive TST, 3/607 (1%) for a positive QFT-GIT, and 7/607
(1%) were referred with no LTBI test (on the basis of a B-waiver).
In the post-QFT-GIT period, 690/750(92%) were referred for
a positive TST alone, 23/750(3%) for a positive QFT-GIT alone,
32/750 (4%) for a B-waiver with no LTBI test, and 5/750(1%)
with both a QFT-GIT and TST performed (Figure 1).
There was no difference in the overall number of referred
individuals that came to BCHD TB clinic for their initial
appointment between the two study periods (452/607 [75%]
and 567/750 [76%] in the pre- and post-QFT-GIT periods,
respectively; p=0.631). Characteristics of individuals adhering to
an initial BCHD TB appointment are shown in Table S1. There
was no difference in age or gender among those adhering to an
initial BCHD evaluation compared to those who did not come for
initial evaluation within either study period. In both study periods,
a significantly higher proportion of foreign-born individuals
adhered to an initial BCHD evaluation compared to US born
individuals (Table S1).
Implementation of QFT-GIT
Among the 567 referrals that came to BCHD for evaluation in
the post-QFT-GIT period, 525 (93%) were referred with a TST,
19 (3%) for a positive QFT-GIT, and 5 (1%) individuals had both
a QFT-GIT and TST performed by referral source; 18 (3%) B-
waiver referrals were evaluated without prior LTBI testing.
Among these 567 referrals, 543 did not have a prior IGRA test
and were eligible for QFT-GIT testing at BCHD. QFT-GIT
testing was performed for 375/543 (69%) eligible individuals
(Figure 1). Individuals coming to the clinic after the courier had
completed daily pick-up of blood specimens were not able to have
QFT-GIT testing performed; time of patient evaluation was not
available and could not be further explored. There was a difference
in implementation of QFT-GIT testing by age (p,0.01), with
a lower proportion of younger children being tested compared to
adults (0/3[0%] in ages 0–2, 3/45[7%] in ages 2–12, 23/36[64%]
in ages 13–17, 258/336[77%] in ages 18–50, and 91/123[74%] in
adults .50). There was also less QFT-GIT testing in individuals
known to be HIV positive (9/17[53%]) compared to individuals
that were HIV-negative (305/288 [79%]; p,0.01). There were no
differences in the proportion tested by gender, birth country, race,
or referral source (Table S2).
Results of QFT-GIT testing
Among the 375 individuals who underwent QFT-GIT testing at
BCHD TB clinic, 185 (49%) were positive by QFT-GIT, 178
(47%) were negative, and 1 (0.25%) was indeterminate, for 11 (3%)
individuals the QFT-GIT test did not yield results due to specimen
processing or transportation errors.
Factors associated with QFT-GIT positivity among those re-
ceiving QFT-GIT at BCHD are shown in Table 2. There were no
differences in age, sex, or ethnicity with regard to QFT-GIT test
positivity. Foreign-born individuals referred for LTBI evaluation
had a higher proportion of QFT-GIT positivity (57%) compared to
US born individuals (36%; AOR 3.3 [95%CI 1.7–6.2]; p,0.01).
Among foreign-born, there were no differences in QFT-GIT
positivity by geographic region of origin (Central/South America
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[33%], Caribbean 1/3 [33%], Other/Unspecified 11/21 [52%];
p=0.382). There was a difference in QFT-GIT test positivity when
comparing referring sources in univariate analysis (Table 2), with
highestQFT-GITpositivityseenamongthosereferredfromrefugee
programs (92/144[64%],OR 2.7[95%CI1.5–4.9];p=0.001)and
other local health departments (22/35 [63%], OR 2.6 [95%CI 1.1-
6.0]; p=0.03). Referral source was not included in multivariate
analysis due to colinearity with birth-country. We observed a trend
in the relationship between QFT-GIT positivity and degree of TST
induration, with increasing QFT-GIT positivity with higher
amountsofTSTinduration,butthisrelationshipwasnotstatistically
significant. QFT-GIT was positive in 3/8 (38%) individuals with
TST between 0–10 mm, 76/184 (41%) of individuals with TST
between 10–15 mm, 59/95 (62%), of those with TST between 15–
20 mm, and 40/59 (68%) of those with TST.20 mm.
Concordance between TST and QFT-GIT tests
During the post-QFT-GIT period, 352 individuals referred for
evaluation had both an interpretable QFT-GIT and an available
TST result available in the post-QFT-GIT period (all 352 TSTs
were performed by the referral source; 347 QFT-GITs were
performed by BCHD and 5 QFT-GITs were performed by the
referral source). Overall, there was only modest agreement
between TST and QFT-GIT (183/352[52.0]%; Table 3). Among
those that were referred with a positive TST result, QFT-GIT was
positive in only 179/344 (52.0%) individuals. Individuals that were
foreign-born were significantly less likely to have discordant results
compared with those that were US-born (41% discordance versus
63% discordance; AOR 0.34 [95% CI 0.18-0.63]; p=0.001;
Table S3). Referral source was also associated with discordance in
univariate analysis, with those referred from refugee services and
local health department programs less likely to have discordance
compared to those referred by primary care doctors or other
health centers (Table S3).
Impact on LTBI Diagnosis and Treatment
We compared programmatic rates of LTBI diagnosis and
treatment in both study periods, and examined the impact of
QFT-GIT testing on diagnosis, treatment initiation, and treatment
completion (Table 4). There was a significant reduction in the
percentage of evaluated individuals that received a final diagnosis
Table 1. Characteristics of individuals referred to Baltimore City Health Department TB Clinic for evaluation of suspected M.
tuberculosis infection, by study period.
Characteristic Referrals
Pre-QFT-GIT Post-QFT-GIT P value
Number 607 750
Evaluated by BCHD during in-person clinic encounter 452 (75%) 567(76%) 0.631
Gender Female 255(42%) 325(43%) 0.624
Male 352(58%) 425(57%)
Age Mean Age(SD) 36.1 (15.3) 36.4 (16.5) 0.77
Foreign-born 363(59%) 507(68%) 0.003
Ethnicity* Black 260(43%) 296(39%) 0.002*
Asian/Pacific Island 199(32%) 224(30%)
Latino 65(11%) 122(17%)
White 43(7%) 35(5%)
Other/Unavailable 40(7%) 73(10%)
HIV { Positive 11/452(2%) 19/567(3%) 0.599
Negative 316/452(70%) 401/567(71%)
Refused/Unknown 125/452(28%) 147/567(26%)
Referral Source: Drug Treatment Program 134 (22%) 104(14%) ,0.001
Refugee 194(32%) 237(32%) 0.904
B-Waiver 25(4%) 72(10%) ,0.001
Health Fairs 19(3%) 40(5%) 0.047
Civil Surgeons 21(3%) 32(4%) 0.441
HIV clinics 7(1%) 17(2%) 0.121
Local Health Departments** 52(9%) 66(9%) 0.879
Dept of Corrections 4(1%) 3(.5%) 0.509
Occupational Health 14(2%) 9(1%) 0.116
Obstetricians 20(3%) 22(3%) 0.706
Primary Care Providers/Other 117(19%) 148(20%) 0.865
Abbreviations: SD, Standard Deviation. BCHD, Baltimore City Health Department.
*Ethnicity data was based on referral documentation and/or initial evaluation at BCHD. P-value for global comparison of equality of proportions of ethnicities by x
2 test.
{HIV test results are available only for those that came to BCHD for evaluation. HIV status not available for those who did not complete an LTBI evaluation at BCHD.
**Includes referrals from other local health departments in Maryland and other states, as well as employment TB testing conducted through other BCHD programs.
doi:10.1371/journal.pone.0036551.t001
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to the pre-QFT-GIT period (445/452 [98%], p,0.001). In
particular, in the post-QFT-GIT period, only 230/399 (58%) of
those receiving QFT-GIT testing had a final diagnosis of LTBI,
while 167/168 (99%) of those without QFT-GIT testing were
diagnosed with LTBI on the basis of the TST result from their
referring source (p,001). Among those with QFT-GIT testing
conducted in the post-QFT-GIT study period, all individuals with
a positive QFT-GIT had a final diagnosis of LTBI (209/209
[100%], while only 10/178 (6%) of those with a negative QFT-
GIT were given a final diagnosis of LTBI on the basis of a positive
TST and clinician judgment. Among these 10 QFT-GIT negative
individuals, reasons given by BCHD clinicians for the diagnosis of
LTBI included HIV-positivity (2), calcified granulomas or other
abnormalities suggestive of TB infection on CXR (3), TST .35 m
(1), young age (2), recent TST conversion within 1 year (2).
Among those given a diagnosis of LTBI, the proportions that
initiated treatment were similar in the pre-QFT-GIT (341/445
[76%]) and post-QFT-GIT periods (307/397 [77%]; p=0.81).
Moreover, there was no difference in treatment initiation in the
post-QFT-GIT period between those diagnosed with LTBI that
had QFT-GIT testing performed (174/230 [76%]) and those that
did not have QFT-GIT testing performed (133/167 [80%],
p=0.349). Among those given a diagnosis of LTBI and adequate
time for treatment, the proportions completing treatment were
similar between the pre-QFT-GIT period (251/445 [56%]) and
the post-QFT-GIT period (174/290 [60%], p=0.335). Treatment
completion proportions, among those that initiated treatment,
were also similar between the pre-QFT-GIT period (251/
341[74%]) and post-QFT-GIT period (174/244 [71%];
p=0.606). In the post-QFT-GIT period, there was no difference
in treatment completion rates between those with and without
QFT-GIT performed (p=0.101). Overall, discontinuation of
therapy for toxicity was similar in the pre-QFT-GIT period (7/
341 (2%) and post-QFT-GIT period (8/244 (3%); p=0.355).
Discussion
We ascertained the clinical impact of QFT-GIT implementa-
tion in a city health department TB control program clinic, as well
as barriers to its implementation. With respect to QFT-GIT
uptake, we found that two-thirds of individuals referred for
suspected M. tuberculosis infection that came for evaluation at
BCHD were tested with QFT-GIT by BCHD after testing became
available. Children were less likely to be tested with QFT-GIT
than were older individuals. Several potential reasons include
difficulty drawing blood in young children, and absence of another
clinical indication for phlebotomy (i.e. liver chemistries are not
routinely performed in healthy children with LTBI), and clinician
discretion; in young children, clinicians at BCHD may have been
more likely to accept a positive TST result in order to maximize
sensitivity in this population in whom IGRA results are more
difficult to interpret. In addition, individuals with HIV-infection
were less likely to be tested with QFT-GIT by BCHD TB clinic,
which may have represented clinician discretion in this high risk
population in whom QFT-GIT has reduced sensitivity. Logistical
challenges associated with QFT-GIT processing were likely the
primary obstacle precluding ordering of the test for all referred
individuals. QFT-GIT processing requires an initial incubation of
blood at 37uC for 16–24 hours shortly after phlebotomy, after
which the specimens can be stored before further processing.
During the post-QFT-GIT period, this initial incubation step was
performed off-site from the BCHD TB clinic. As a result, the clinic
could not offer the test to individuals arriving in the late afternoon
because of a need for specimen transport via courier before
laboratory closure. A potential solution is to obtain an incubator
for use in the TB clinic so that incubation can be initiated in the
Figure 1. Flow of LTBI patient evaluation and testing at BCHD in the post-QFT-GIT period. *Among 750 referrals, 690 had a TST by
referring source, 23 had a QFT-GIT by the referring source, and 5 had both a QFT-GIT and TST performed by referral source); 32 individuals were
referred as B-Waivers without prior LTBI testing based on abnormal CXR during immigration. Among 567 referrals that came to BCHD for evaluation,
525 were referred with a TST result and 19 for a positive QFT-GIT and 5 individuals had both a QFT-GIT and TST performed by referral source; 18 B-
waiver referrals were evaluated without prior LTBI testing. Among these 567 referrals, 168 had only a TST (30%), 37 had only a QFT-GIT (67), and 362
(64%) had both a TST and a QFT-GIT test result. Of 399 QFT-GIT test results among referrals evaluated by BCHD, 375 had QFT-GIT testing at BCHD and
24 had QFT-GIT testing from referral source.
doi:10.1371/journal.pone.0036551.g001
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until receipt of specimens in the off-site laboratory.
Despite these challenges, there was a low proportion of test
failure, with 97% of drawn QFT-GIT tests yielding interpretable
results and a very low proportion of indeterminate tests (,1%).
On balance, our experience suggests that implementation of QFT-
GIT in local health departments is likely to be feasible, but
requires attention to specimen transport schedules and/or in-clinic
initiation of sample incubation, and to training of clinic staff in
drawing blood from children if QFT-GIT testing of children is
considered part of routine care.
Importantly, implementation of QFT-GIT testing in the BCHD
TB clinic had a significant programmatic impact on LTBI
diagnosis of referred individuals. In Baltimore City, individuals
are referred to the BCHD TB clinic with suspected LTBI on the
basis of community-based testing, usually for a positive TST.
Table 2. Factors associated with QFT-GIT test positivity among those tested at BCHD.
Characteristic Referral for LTBI OR AOR
N
QFT-GIT
positive(%)
QFT-GIT performed by BCHD 375 *
Interpretable QFT-GIT result available 363* 185 (51%)
Gender Female 166 81 (49%) REF REF
Male 197 104 (53%) 1.2(.78–1.8) 1.2(0.79–2.0)
Age 0-2 0 – – –
2-12 3 1 (33%) 0.46 (0.03–5.2) 0.11(0.01–1.5)
13-17 23 11 (48%) 0.83(.33–2.1) 0.39(0.14–1.2)
18-50 251 128 (51%) 0.94(.58–1.5) 0.59(0.32–1.1)
.50 86 45 (52%) REF REF
Birthplace Not Foreign-born 107 39 (36%) REF REF
Foreign-born 256 146(57%) 2.3 (1.4–3.7) u 3.3(1.7–6.2)u
Ethnicity White 18 7 (39%) REF REF
u Asian/Pacific Island 123 70 (56%) 2.1 (0.75–5.7) 1.2(0.37–3.9)
u Black 150 77(51%) 1.6 (0.61–4.5) 1.3(0.45–4.0)
u Latino 56 26(46%) 1.4(0.47–4.0) 0.73(0.21–2.5)
u Other/Unavailable 16 5(31%) 0.7(0.17–3.0) 0.73(0.16–3.3)
HIV Positive 9 1(11%) .011 (0.01–0.92) uu 0.17(0.02–1.77)
u Negative 295 154 (52%) REF REF
Unknown 59 30 (51%) 0.94 (.54–1.7) 1.6(0.80–3.1)
Referral Source: Drug Treatment Programs 44 14 (32%) 0.70(0.3–1.6) {
u Refugee Services 144 92 (64%) 2.7 (1.5–4.9) {{
B-Waiver 34 16 (47%) 1.4 (0.58–3.1)
Health Fairs 18 8 (44%) 1.2(0.42–3.5)
u Immigration/Civil Surgeons 6 3 (50%) 1.5(0.28–8.1)
u HIV 8 1(13%) 0.22 (0.02–1.9)
u Local Health Departments 35 22(63%) 2.6 (1.1–6.0) {{
Dept of Corrections 1 0 (0%) –
Occupational Health 4 3 (75) 4.6 (0.45–46)
Obstetricians 6 1 (16%) 0.3 (0.03–2.8)
Primary Care Providers/Other 63 25 (40%) REF
TST Induration 0–10mm 3(38%) REF REF
10–15mm 184 76(41%) 1.2 (0.27–5.1) 0.99(0.18–5.5)
15–20mm 95 59(62%) 2.7 (0.6–12) 2.4(0.41–13.9)
.20mm 59 40(68%) 3.5(0.8–16) 2.8(0.47–16.7)
Only individuals with QFT-GIT performed by BCHD are included. 11 individuals had blood drawn for QFT-GIT but did not have interpretable results due to insufficient
blood volume during venipuncture, sample transportation issues, or processing error. There was 1 indeterminate result.
up,0.001 for both univariate and multivariate analysis comparing foreign-born to US born individuals.
uu P=0.042 comparing HIV positive to HIV negative individuals.
{Referral source was omitted from multivariate regression model due to collinearity with birth country.
{{p=0.001 comparing those referred from Refugee health services to those referred from primary care providers/other; p=0.03 comparing those referred from local
health departments to those referred from primary care providers/other.
doi:10.1371/journal.pone.0036551.t002
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resulted in a final diagnosis of LTBI in the period after QFT-GIT
implementation compared to a similar time period prior to test
implementation. This reduction was driven by the additional
QFT-GIT testing conducted by BCHD on LTBI referrals. In both
study periods, nearly all referred individuals not receiving BCHD
directed QFT-GIT testing had a final diagnosis of LTBI, with
reliance on TST data from the referral source. In contrast, only
58% of individuals referred for LTBI evaluation were given a final
diagnosis of LTBI if QFT-GIT was performed by BCHD as part
of the diagnostic evaluation. Interestingly, while the proportion of
individuals with LTBI diagnosis was reduced in the post-QFT-
GIT period, there was no difference in the proportion of
individuals that initiated or completed LTBI treatment between
the study periods. This finding suggests that choice of diagnostic
test did not influence patient behavior with regards to starting or
completing treatment in our setting.
Our study evaluated factors associated with QFT-GIT positivity
and offers important insights into QFT-GIT test performance and
concordance with TST under operational conditions. Overall, the
QFT-GIT test was positive in only half of the individuals referred
to BCHD as having possible M. tuberculosis infection and agreed
with TST results in only 52% of cases. These results suggest that
TST positivity from community-based testing may have sub-
optimal positive predictive value for M. tuberculosis infection. This
finding is similar to that reported in other low-prevalence settings
when QFT-GIT was performed on TST positive referrals [9].
Interestingly, foreign-born individuals had higher proportions of
QFT-GIT positivity (57%) compared to US-born individuals
(36%) among LTBI referrals. This finding may reflect the higher
risk of LTBI for foreign-born individuals from endemic settings,
compared to US-born individuals. It also may speak to the
technical difficulties with performing and interpreting TSTs,
particularly in low-prevalence settings. Nonetheless, even among
foreign-born individuals, overall QFT-GIT positivity and TST
concordance were relatively low, which may indicate suboptimal
TST specificity in BCG vaccinated populations. There were also
differences in QFT-GIT positivity based on referral source in
univariate analysis, which may represent the challenges in
reliability of TST results when performed by heterogenous sources
in the community.
Our study has several important limitations. Our study popula-
tion consisted of individuals who were referred to the health
department on the basis of prior suspicion or diagnosis of latent TB.
QFT-GIT positivity and concordance with TST may differ when
performed in an unselected group from the general population.
Nonetheless,theBCHDTBprogramstructureisnotdissimilarfrom
many public health TB programs in the US, and our results have
relevance for urban local health departments and other facilities
Table 3. Concordance of TST and QFT-GIT results among
referred individuals that came to BCHD for LTBI evaluation
and had both tests performed.
TST negative TST positive Total
QFT-GIT
negative
4 (1%)* 164 (47%) 168
QFT-GIT
positive
4 (1%)* 179 (51%) 183
QFT-GIT
indeterminate
0 1 (0.25%) 1
Total 8 344 352{
{Overall, 352 individuals had a TST and interpretable QFT-GIT result available.
There was an overall concordance of 52.3%.
*8 individuals with negative TST results were referred and evaluated by BCHD. 4
individuals with B-waivers had negative TST, but were referred due to an
abnormal CXR; 4 individuals had both TST and QFT-GIT performed by referral
source.
doi:10.1371/journal.pone.0036551.t003
Table 4. Differences in LTBI diagnosis among referrals to BCHD between study periods and by QFT-GIT test status.
Group QFT-GIT category Referral N
Evaluated by
BCHD N (%)
Diagnosed
LTBI N (%)
Initiation of
treatment N (%)**
Completion of
treatment{
Pre-QFT-GIT Total 607 452 (75%) 445 (98%)u 341 (77%) 251 (74%)
QFT-GIT performed 3 (1%)* 3 (100%)uu 2 (66%) 2(100%)
N QFT-GIT negative N – N – N – N –
N QFT-GIT positive N 3 (100%) N 3 (100%) N 2 (66%) N 2 (100%)
No QFT-GIT performed 449 (99%) 442 (98%)uu 339 (77%) 249(78%)
Post-QFT-GIT Total 750 567 (76%) 397(70%)u 307 (77%) 174/244 (75%)
QFT-GIT performed 399 (70%)* 230 (58%)uu 174 (76%) 105/137(77%)
N QFT-GIT negative N 178 (45%) N 10 (6%) N 10(100%) N 4/7(57%)
N QFT-GIT positive N 209 (52%) N 209 (100%) N 157(75%) N 97/120(81%)
No QFT-GIT performed 168 (30%) 167 (99%)uu 133 (80%) 69/107(65%)
*includes individuals that had QFT-GIT performed by referral source. 11/399 individuals in the post-QFT-GIT period had QFT-GIT drawn but no results available; there
was 1 indeterminate result in the post-QFT-GIT-period.
up,.001 comparing final diagnosis of LTBI between pre-QFT-GIT and post-QFT-GIT periods.
uup=.827 for pre-QFT-GIT period comparing LTBI diagnosis between those with and without a QFT-GIT result; p,.001 in post-QFT-GIT period comparing LTBI diagnosis
between those with and without QFT-GIT performed.
**p=.81 comparing treatment initiation among those diagnosed with LTBI between pre-QFT-GIT and post-QFT-GIT periods; p=0.690 comparing treatment initiation
between those with and without QFT-GIT performed in the pre-QFT-GIT period; p=.349 comparing treatment intiation between those with and without QFT-GIT
performed in the post-QFT-GIT period.
{Analysis restricted to those who started an INH X 9 months regimen prior to Nov 30, 2010 or Rifampin X 4 months prior to March 30, 2011 to allow time for completion.
p=.606 comparing overall treatment completion between pre-QFT-GIT period and post-QFT-GIT period. p=0.101 comparing those with and without QFT-GIT
performed in the post-QFT-GIT period; p=0.70 comparing those with and without QFT-GIT in the pre-QFT-GIT period.
doi:10.1371/journal.pone.0036551.t004
QFT-GIT Implementation in Baltimore City
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36551providinglatentTBservices.Withoutareferencestandardforlatent
TBdiagnosis,interpretationofTSTandQFT-GITdiscordancecan
be challenging [15]. Discordance, conversions, and reversions of
both tests are known to occur and may be the result of intra-
individual variability, timing related to TB exposure, host immu-
nologic responses, laboratory or test procedures, or cross-reactivity
with BCG. The CDC thus currently recommends that in persons
with discordant test results, decisions should be made on an
individual basis considering aspects that include the degree of TST
induration, BCG vaccination status, quantitative QFT-GIT results,
the probability of infection, and the risk of disease if infected [7]. All
patients referred for evaluation at BCHD received an individual
assessment based on these considerations; nonetheless our results
suggest that the majority of individuals evaluated at BCHD with
negative QFT-GIT results were considered to not have LTBI and
were not initiated on treatment. Long term clinical outcomes in
individuals with a positive TST but negative QFT-GIT are
currently unknown. As such, clinical interpretations of discordant
results and treatment decisions may differ in other settings based on
patient risk factors or local epidemiologic considerations. While
BCG vaccination status is assessed by BCHD clinicians, this data
was not systematically recorded in BCHD records and thus any
impact of BCG vaccination on test results could not be evaluated in
this study. Our study was also limited to assessing the impact of
QFT-GIT testing on LTBI diagnosis and treatment among only
referred individuals. BCHD additionally performs LTBI evalua-
tions in individuals that are close-contacts of active TB cases. To
date, however, due to logistical challenges of performing phlebot-
omyinthefield,fewindividualsreceivedQFT-GITtestingaspartof
BCHD contact investigations, and they were not considered as part
of this study. Lastly, as this study was a retrospective cohort analysis
comparing two different periods of time, we cannot exclude the
possibility that temporal trends could have influenced the results.
Our study also has several important strengths. In contrast to
studies of QFT-GIT diagnostic accuracy, we evaluated the
programmatic impact of implementing this new TB diagnostic
modality in a large urban public health department under realistic
operational conditions. We also report on factors associated with
QFT-GIT positivity which may help guide other local health
departments considering test implementation. With continued
reductions in public health resources, our study has important
implications for local TB prevention programs. Overall, we found
that QFT-GIT implementation led to significant reductions in
LTBI diagnosis and treatment at BCHD. Future studies are now
needed to determine the cost-effectiveness of QFT-GIT imple-
mentation, and to examine TB reactivation rates in QFT-GIT and
TST discordant patients.
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